{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:53:22Z","timestamp":1793814802504,"version":"4.6.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,17]]},"DOI":"10.7759\/cureus.67054","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T09:24:16Z","timestamp":1723886656000},"source":"Crossref","is-referenced-by-count":6,"title":["Acute Phase Peyronie\u2019s Disease: Where Do We Stand?"],"prefix":"10.7759","author":[{"given":"Konstantinos","family":"Douroumis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kotrotsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Katsikatsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napoleon","family":"Moulavasilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Fragkiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Mitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Adamakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13224","article-title":"Peyronie's disease development and management in diabetic men","volume":"11","author":"Gianazza S","year":"2023","unstructured":"Gianazza S, Belladelli F, Leni R, et al.. Peyronie's disease development and management in diabetic men. Andrology. 2023, 11:372-8. 10.1111\/andr.13224","journal-title":"Andrology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey","volume":"88","author":"Schwarzer U","year":"2001","unstructured":"Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001, 88:727-30. 10.1046\/j.1464-4096.2001.02436.x","journal-title":"BJU Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti DB","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States. Adv Urol. 2011, 2011:282503. 10.1155\/2011\/282503","journal-title":"Adv Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: a population-based study","volume":"11","author":"Stuntz M","year":"2016","unstructured":"Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie's disease in the United States: a population-based study. PLoS One. 2016, 11:e0150157. 10.1371\/journal.pone.0150157","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11930-015-0045-y","article-title":"Peyronie\u2019s disease: a review of etiology, diagnosis, and management","volume":"7","author":"Bilgutay AN","year":"2015","unstructured":"Bilgutay AN, Pastuszak AW. Peyronie\u2019s disease: a review of etiology, diagnosis, and management. Curr Sex Health Rep. 2015, 7:117-31. 10.1007\/s11930-015-0045-y","journal-title":"Curr Sex Health Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/2156-7514.103053","article-title":"US imaging in Peyronie's disease","volume":"2","author":"Kalokairinou K","year":"2012","unstructured":"Kalokairinou K, Konstantinidis C, Domazou M, Kalogeropoulos T, Kosmidis P, Gekas A. US imaging in Peyronie's disease. J Clin Imaging Sci. 2012, 2:63. 10.4103\/2156-7514.103053","journal-title":"J Clin Imaging Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall JP","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006, 175:2115-8; discussion 2118. 10.1016\/S0022-5347(06)00270-9","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"5","author":"Al-Thakafi S","year":"2016","unstructured":"Al-Thakafi S, Al-Hathal N. Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol. 2016, 5:280-9. 10.21037\/tau.2016.04.05","journal-title":"Transl Androl Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The chronology of depression and distress in men with Peyronie's disease","volume":"5","author":"Nelson CJ","year":"2008","unstructured":"Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie's disease. J Sex Med. 2008, 5:1985-90. 10.1111\/j.1743-6109.2008.00895.x","journal-title":"J Sex Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie's disease: a review","volume":"10","author":"Nelson CJ","year":"2013","unstructured":"Nelson CJ, Mulhall JP. Psychological impact of Peyronie's disease: a review. J Sex Med. 2013, 10:653-60. 10.1111\/j.1743-6109.2012.02999.x","journal-title":"J Sex Med"},{"key":"ref11","unstructured":"Guidelines. (2023). Accessed. July 22, 2024: https:\/\/uroweb.org\/guidelines."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2003.12.002","article-title":"L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures","volume":"9","author":"Valente EG","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003, 9:229-44. 10.1016\/j.niox.2003.12.002","journal-title":"Nitric Oxide"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1949.tb55300.x","article-title":"The use of tocopherols in the treatment of Peyronie's disease","volume":"52","author":"Scardino PL","year":"1949","unstructured":"Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann New York Acad Sci. 1949, 52:390-3. 10.1111\/j.1749-6632.1949.tb55300.x","journal-title":"Ann New York Acad Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1975.tb03951.x","article-title":"Treatment of Peyronie's disease with procarbazine","volume":"47","author":"Oosterlinck W","year":"1975","unstructured":"Oosterlinck W, Renders G. Treatment of Peyronie's disease with procarbazine. Br J Urol. 1975, 47:219-20. 10.1111\/j.1464-410x.1975.tb03951.x","journal-title":"Br J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S97194","article-title":"Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study","volume":"8","author":"Paulis G","year":"2016","unstructured":"Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, Gennaro R. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Res Rep Urol. 2016, 8:1-10. 10.2147\/RRU.S97194","journal-title":"Res Rep Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad MR","year":"2010","unstructured":"Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010, 22:298-309. 10.1038\/ijir.2010.20","journal-title":"Int J Impot Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report","volume":"88","author":"Biagiotti G","year":"2001","unstructured":"Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001, 88:63-7. 10.1046\/j.1464-410x.2001.02241.x","journal-title":"BJU Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.12.003","article-title":"Assessment of conservative combination therapies for active and stable Peyronie's disease: a systematic review and meta-analysis","volume":"8","author":"Pyrgidis N","year":"2022","unstructured":"Pyrgidis N, Yafi FA, Sokolakis I, et al.. Assessment of conservative combination therapies for active and stable Peyronie's disease: a systematic review and meta-analysis. Eur Urol Focus. 2022, 8:1520-30. 10.1016\/j.euf.2021.12.003","journal-title":"Eur Urol Focus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)66108-1","article-title":"Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (potaba)","volume":"81","author":"Zarafonetis CJD","year":"1959","unstructured":"Zarafonetis CJD, Horrax TM. Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (potaba). J Urol. 1959, 81:770-2. 10.1016\/S0022-5347(17)66108-1","journal-title":"J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1992.tb15836.x","article-title":"The treatment of Peyronie's disease with tamoxifen","volume":"70","author":"Ralph DJ","year":"1992","unstructured":"Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992, 70:648-51. 10.1111\/j.1464-410x.1992.tb15836.x","journal-title":"Br J Urol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract12060105","article-title":"Disappearance of plaque following treatment with antioxidants in Peyronie's disease patients-a report of 3 cases","volume":"12","author":"Paulis G","year":"2022","unstructured":"Paulis G, De Giorgio G. Disappearance of plaque following treatment with antioxidants in Peyronie's disease patients-a report of 3 cases. Clin Pract. 2022, 12:1020-33. 10.3390\/clinpract12060105","journal-title":"Clin Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2174\/1871528112666131205112432","article-title":"Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study","volume":"12","author":"Paulis G","year":"2013","unstructured":"Paulis G, Cavallini G, Giorgio GD, Quattrocchi S, Brancato T, Alvaro R. Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study. Inflamm Allergy Drug Targets. 2013, 12:403-9. 10.2174\/1871528112666131205112432","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000049797","article-title":"Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease","volume":"40","author":"Riedl CR","year":"2001","unstructured":"Riedl CR, Plas E, Vorauer K, Vcelar B, Wagner A, Pfl\u00fcger H. Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease. Eur Urol. 2001, 40:343-8; discussion 348-9. 10.1159\/000049797","journal-title":"Eur Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00916-4","article-title":"Efficacy of collagenase Clostridium histolyticum (Xiapex(\u00ae)) in patients with the acute phase of Peyronie\u2019s disease","volume":"40","author":"Cocci A","year":"2020","unstructured":"Cocci A, Di Maida F, Russo GI, et al.. Efficacy of collagenase Clostridium histolyticum (Xiapex(\u00ae)) in patients with the acute phase of Peyronie\u2019s disease. Clin Drug Investig. 2020, 40:583-8. 10.1007\/s40261-020-00916-4","journal-title":"Clin Drug Investig"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)35291-6","article-title":"Intralesional verapamil injection for the treatment of Peyronie's disease","volume":"151","author":"Levine LA","year":"1994","unstructured":"Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994, 151:1522-4. 10.1016\/s0022-5347(17)35291-6","journal-title":"J Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esxm.2016.01.002","article-title":"Intralesional injection of hyaluronic acid in patients affected with Peyronie's disease: preliminary results from a prospective, multicenter, pilot study","volume":"4","author":"Zucchi A","year":"2016","unstructured":"Zucchi A, Costantini E, Cai T, et al.. Intralesional injection of hyaluronic acid in patients affected with Peyronie's disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016, 4:e83-8. 10.1016\/j.esxm.2016.01.002","journal-title":"Sex Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13754","article-title":"Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: a single-centre, preliminary prospective non-randomised study","volume":"75","author":"Ure I","year":"2021","unstructured":"Ure I, Ozen A. Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: a single-centre, preliminary prospective non-randomised study. Int J Clin Pract. 2021, 75:e13754. 10.1111\/ijcp.13754","journal-title":"Int J Clin Pract"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01924.x","article-title":"Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh J","year":"2010","unstructured":"Soh J, Kawauchi A, Kanemitsu N, et al.. Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med. 2010, 7:3743-9. 10.1111\/j.1743-6109.2010.01924.x","journal-title":"J Sex Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study","volume":"67","author":"Inal T","year":"2006","unstructured":"Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology. 2006, 67:1038-42. 10.1016\/j.urology.2005.11.005","journal-title":"Urology"},{"key":"ref30","article-title":"Extra-corporeal lithotripsy in the treatment of Peyronie's disease. Use of a standard lithotriptor (Multiline Siemens) on \"young\" (less then 6 months old) plaques (Article in French)","volume":"10","author":"Lebret T","year":"2000","unstructured":"Lebret T, Herv\u00e9 JM, Lugagne PM, Barr\u00e9 P, Orsini JL, Butreau M, Botto H. Extra-corporeal lithotripsy in the treatment of Peyronie's disease. Use of a standard lithotriptor (Multiline Siemens) on \"young\" (less then 6 months old) plaques (Article in French). Prog Urol. 2000, 10:65-70; discussion 70-1.","journal-title":"Prog Urol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12400","article-title":"Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Mart\u00ednez-Salamanca JI","year":"2014","unstructured":"Mart\u00ednez-Salamanca JI, Egui A, Moncada I, et al.. Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014, 11:506-15. 10.1111\/jsm.12400","journal-title":"J Sex Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.05.004","article-title":"Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: pilot study","volume":"32","author":"Schirmann A","year":"2022","unstructured":"Schirmann A, Boutin E, Faix A, Yiou R. Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: pilot study. Prog Urol. 2022, 32:856-61. 10.1016\/j.purol.2022.05.004","journal-title":"Prog Urol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(01)65361-8","article-title":"Proposal: trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine CJ Jr","year":"1997","unstructured":"Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997, 157:285-90. 10.1016\/s0022-5347(01)65361-8","journal-title":"J Urol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.173107","article-title":"Peyronie's disease: what's around the bend?","volume":"32","author":"Bilgutay AN","year":"2016","unstructured":"Bilgutay AN, Pastuszak AW. Peyronie's disease: what's around the bend?. Indian J Urol. 2016, 32:6-14. 10.4103\/0970-1591.173107","journal-title":"Indian J Urol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12129","article-title":"Understanding the course of Peyronie's disease","volume":"67","author":"Garaffa G","year":"2013","unstructured":"Garaffa G, Trost LW, Serefoglu EC, Ralph D, Hellstrom WJ. Understanding the course of Peyronie's disease. Int J Clin Pract. 2013, 67:781-8. 10.1111\/ijcp.12129","journal-title":"Int J Clin Pract"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The genetic basis of Peyronie disease: a review","volume":"4","author":"Herati AS","year":"2016","unstructured":"Herati AS, Pastuszak AW. The genetic basis of Peyronie disease: a review. Sex Med Rev. 2016, 4:85-94. 10.1016\/j.sxmr.2015.10.002","journal-title":"Sex Med Rev"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nri2852","article-title":"The impact of the extracellular matrix on inflammation","volume":"10","author":"Sorokin L","year":"2010","unstructured":"Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. 2010, 10:712-23. 10.1038\/nri2852","journal-title":"Nat Rev Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2017.06.004","article-title":"Extracellular matrix alterations in the Peyronie's disease","volume":"8","author":"Watanabe MS","year":"2017","unstructured":"Watanabe MS, Theodoro TR, Coelho NL, et al.. Extracellular matrix alterations in the Peyronie's disease. J Adv Res. 2017, 8:455-61. 10.1016\/j.jare.2017.06.004","journal-title":"J Adv Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.09.009","article-title":"Reciprocal regulation of TGF-\u03b2 and reactive oxygen species: a perverse cycle for fibrosis","volume":"6","author":"Liu RM","year":"2015","unstructured":"Liu RM, Desai LP. Reciprocal regulation of TGF-\u03b2 and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol. 2015, 6:565-77. 10.1016\/j.redox.2015.09.009","journal-title":"Redox Biol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.01.010","article-title":"Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque","volume":"65","author":"Davila HH","year":"2005","unstructured":"Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology. 2005, 65:645-8. 10.1016\/j.urology.2005.01.010","journal-title":"Urology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.01.093","article-title":"Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts","volume":"179","author":"Del Carlo M","year":"2008","unstructured":"Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol. 2008, 179:2447-55. 10.1016\/j.juro.2008.01.093","journal-title":"J Urol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-5-S1-S24","article-title":"CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis","volume":"5","author":"Lipson KE","year":"2012","unstructured":"Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012, 5:S24. 10.1186\/1755-1536-5-S1-S24","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2011.11.008","article-title":"Drugs of the future for Peyronie's disease","volume":"78","author":"Gur S","year":"2012","unstructured":"Gur S, Kadowitz PJ, Hellstrom WJ. Drugs of the future for Peyronie's disease. Med Hypotheses. 2012, 78:305-11. 10.1016\/j.mehy.2011.11.008","journal-title":"Med Hypotheses"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/01485010500203667","article-title":"Histologic study of the tunica albuginea of the penis and mode of cavernosus muscles' insertion in it","volume":"52","author":"Shafik A","year":"2006","unstructured":"Shafik A, El-Sharkawy A, Khamis A, Zaghloul S, Abdel Gawad M, Elwy D. Histologic study of the tunica albuginea of the penis and mode of cavernosus muscles' insertion in it. Arch Androl. 2006, 52:1-8. 10.1080\/01485010500203667","journal-title":"Arch Androl"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64129-8","article-title":"Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease","volume":"169","author":"Hauck EW","year":"2003","unstructured":"Hauck EW, Hauptmann A, Schmelz HU, Bein G, Weidner W, Hackstein H. Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease. J Urol. 2003, 169:369-72. 10.1016\/S0022-5347(05)64129-8","journal-title":"J Urol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)44170-x","article-title":"Chromosome abnormalities in Peyronie's disease","volume":"137","author":"Somers KD","year":"1987","unstructured":"Somers KD, Winters BA, Dawson DM, et al.. Chromosome abnormalities in Peyronie's disease. J Urol. 1987, 137:672-5. 10.1016\/s0022-5347(17)44170-x","journal-title":"J Urol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02704.x","article-title":"WNT2 locus is involved in genetic susceptibility of Peyronie's disease","volume":"9","author":"Dolmans GH","year":"2012","unstructured":"Dolmans GH, Werker PM, de Jong IJ, Nijman RJ, Wijmenga C, Ophoff RA. WNT2 locus is involved in genetic susceptibility of Peyronie's disease. J Sex Med. 2012, 9:1430-4. 10.1111\/j.1743-6109.2012.02704.x","journal-title":"J Sex Med"},{"key":"ref48","article-title":"Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea","volume":"21","author":"Zorba OU","year":"2012","unstructured":"Zorba OU, Sirma S, Ozgon G, Salabas E, Ozbek U, Kadioglu A. Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea. Adv Clin Exp Med. 2012, 21:607-14.","journal-title":"Adv Clin Exp Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100447","article-title":"Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis","volume":"187","author":"Wynes MW","year":"2011","unstructured":"Wynes MW, Edelman BL, Kostyk AG, et al.. Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis. J Immunol. 2011, 187:527-37. 10.4049\/jimmunol.1100447","journal-title":"J Immunol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12812","article-title":"Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease","volume":"114","author":"Kwon KD","year":"2014","unstructured":"Kwon KD, Choi MJ, Park JM, et al.. Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease. BJU Int. 2014, 114:926-36. 10.1111\/bju.12812","journal-title":"BJU Int"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.200065","article-title":"The natural history of Peyronie's disease","volume":"39","author":"Di Maida F","year":"2021","unstructured":"Di Maida F, Cito G, Lambertini L, et al.. The natural history of Peyronie's disease. World J Mens Health. 2021, 39:399-405. 10.5534\/wjmh.200065","journal-title":"World J Mens Health"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12346","article-title":"Deformity stabilization and improvement in men with untreated Peyronie's disease","volume":"113","author":"Berookhim BM","year":"2014","unstructured":"Berookhim BM, Choi J, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie's disease. BJU Int. 2014, 113:133-6. 10.1111\/bju.12346","journal-title":"BJU Int"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_74_20","article-title":"Role of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in Peyronie's disease: a new diagnostic approach to predict the stage of the disease?","volume":"23","author":"Garcia Rojo E","year":"2021","unstructured":"Garcia Rojo E, Garc\u00eda G\u00f3mez B, Santos-P\u00e9rez de la Blanca R, et al.. Role of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in Peyronie's disease: a new diagnostic approach to predict the stage of the disease?. Asian J Androl. 2021, 23:325-9. 10.4103\/aja.aja_74_20","journal-title":"Asian J Androl"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2012.92","article-title":"Surgery for Peyronie's disease","volume":"15","author":"Levine LA","year":"2013","unstructured":"Levine LA, Larsen SM. Surgery for Peyronie's disease. Asian J Androl. 2013, 15:27-34. 10.1038\/aja.2012.92","journal-title":"Asian J Androl"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15057","article-title":"A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association","volume":"126 Suppl 1","author":"Chung E","year":"2020","unstructured":"Chung E, Gillman M, Tuckey J, La Bianca S, Love C. A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association. BJU Int. 2020, 126 Suppl 1:12-7. 10.1111\/bju.15057","journal-title":"BJU Int"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2018.09.007","article-title":"Review of management options for active-phase Peyronie's disease","volume":"7","author":"Brimley SC","year":"2019","unstructured":"Brimley SC, Yafi FA, Greenberg J, Hellstrom WJ, Tue Nguyen HM, Hatzichristodoulou G. Review of management options for active-phase Peyronie's disease. Sex Med Rev. 2019, 7:329-37. 10.1016\/j.sxmr.2018.09.007","journal-title":"Sex Med Rev"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1978.tb03038.x","article-title":"Procarbazine (Natulan) in the treatment of Peyronie's disease","volume":"50","author":"Morgan RJ","year":"1978","unstructured":"Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie's disease. Br J Urol. 1978, 50:111-3. 10.1111\/j.1464-410x.1978.tb03038.x","journal-title":"Br J Urol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(94)80155-x","article-title":"Is colchicine effective in Peyronie's disease? A pilot study","volume":"44","author":"Akkus E","year":"1994","unstructured":"Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology. 1994, 44:291-5. 10.1016\/s0090-4295(94)80155-x","journal-title":"Urology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900519","article-title":"Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome","volume":"12","author":"Kadioglu A","year":"2000","unstructured":"Kadioglu A, Tefekli A, K\u00f6ksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000, 12:169-75. 10.1038\/sj.ijir.3900519","journal-title":"Int J Impot Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900635","article-title":"Peyronie's disease in men under age 40: characteristics and outcome","volume":"13","author":"Tefekli A","year":"2001","unstructured":"Tefekli A, Kandirali E, Erol H, Alp T, K\u00f6ksal T, Kadio\u011flu A. Peyronie's disease in men under age 40: characteristics and outcome. Int J Impot Res. 2001, 13:18-23. 10.1038\/sj.ijir.3900635","journal-title":"Int J Impot Res"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad MR","year":"2004","unstructured":"Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004, 16:238-43. 10.1038\/sj.ijir.3901185","journal-title":"Int J Impot Res"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0272.2009.01004.x","article-title":"The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side","volume":"43","author":"Akman T","year":"2011","unstructured":"Akman T, Sanli O, Uluocak N, Akbulut F, Nane I, Demir S, Kadioglu A. The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side. Andrologia. 2011, 43:28-33. 10.1111\/j.1439-0272.2009.01004.x","journal-title":"Andrologia"},{"key":"ref64","article-title":"Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA) (author's transl) (Article in German)","volume":"17","author":"Hasche-Kl\u00fcnder R","year":"1978","unstructured":"Hasche-Kl\u00fcnder R. Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA) (author's transl) (Article in German). Urologe A. 1978, 17:224-7.","journal-title":"Urologe A"},{"key":"ref65","article-title":"A multicentre doubleblind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease","volume":"9","author":"Shah PJ","year":"1983","unstructured":"Shah PJ, Green NA, Adib RS, Pryor JP. A multicentre doubleblind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease. Prog Reprod Biol Med . 1983, 9:61-7.","journal-title":"Prog Reprod Biol Med"},{"key":"ref66","article-title":"Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?","volume":"3","author":"Carson CC","year":"1997","unstructured":"Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?. Tech Urol. 1997, 3:135-9.","journal-title":"Tech Urol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner W","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005, 47:530-5; discussion 535-6. 10.1016\/j.eururo.2004.12.022","journal-title":"Eur Urol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor","volume":"34","author":"Park TY","year":"2016","unstructured":"Park TY, Jeong HG, Park JJ, et al.. The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor. World J Mens Health. 2016, 34:40-6. 10.5534\/wjmh.2016.34.1.40","journal-title":"World J Mens Health"},{"key":"ref69","article-title":"Controlled clinical trial of vitamin E in Peyronie's disease","volume":"9","author":"Pryor JP","year":"1983","unstructured":"Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol Med. 1983, 9:41-5.","journal-title":"Prog Reprod Biol Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01270.x","article-title":"Outcome analysis for conservative management of Peyronie's disease","volume":"13","author":"Hashimoto K","year":"2006","unstructured":"Hashimoto K, Hisasue S, Kato R, Kobayashi K, Shimizu T, Tsukamoto T. Outcome analysis for conservative management of Peyronie's disease. Int J Urol. 2006, 13:244-7. 10.1111\/j.1442-2042.2006.01270.x","journal-title":"Int J Urol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad MR","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007, 178:1398-403; discussion 1403. 10.1016\/j.juro.2007.05.162","journal-title":"J Urol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases","volume":"1","author":"Paulis G","year":"2013","unstructured":"Paulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013, 1:120-8. 10.1111\/j.2047-2927.2012.00007.x","journal-title":"Andrology"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie's disease","volume":"162","author":"Teloken C","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999, 162:2003-5. 10.1016\/S0022-5347(05)68087-1","journal-title":"J Urol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1093\/jsxmed\/qdad083","article-title":"A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals","volume":"20","author":"Cellek S","year":"2023","unstructured":"Cellek S, Megson M, Ilg MM, Ralph DJ. A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals. J Sex Med. 2023, 20:1057-9. 10.1093\/jsxmed\/qdad083","journal-title":"J Sex Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02217.x","article-title":"The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes","volume":"8","author":"Chung E","year":"2011","unstructured":"Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011, 8:1472-7. 10.1111\/j.1743-6109.2011.02217.x","journal-title":"J Sex Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction","volume":"183","author":"Ozturk U","year":"2014","unstructured":"Ozturk U, Yesil S, Goktug HN, et al.. Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction. Ir J Med Sci. 2014, 183:449-53. 10.1007\/s11845-013-1036-5","journal-title":"Ir J Med Sci"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-022-00651-8","article-title":"Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis","volume":"36","author":"Spirito L","year":"2024","unstructured":"Spirito L, Manfredi C, La Rocca R, et al.. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis. Int J Impot Res. 2024, 36:129-34. 10.1038\/s41443-022-00651-8","journal-title":"Int J Impot Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2022.3.319","article-title":"Effects of long term sildena\ufb01l on the acute phase of Peyronie's disease in a combination treatment","volume":"94","author":"Topcuoglu M","year":"2022","unstructured":"Topcuoglu M, \u00c7akan M. Effects of long term sildena\ufb01l on the acute phase of Peyronie's disease in a combination treatment. Arch Ital Urol Androl. 2022, 94:319-22. 10.4081\/aiua.2022.3.319","journal-title":"Arch Ital Urol Androl"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.011","article-title":"Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study","volume":"48","author":"Riedl CR","year":"2005","unstructured":"Riedl CR, Sternig P, Gall\u00e9 G, et al.. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005, 48:656-61. 10.1016\/j.eururo.2005.04.011","journal-title":"Eur Urol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/ijir.2015.22","article-title":"Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study","volume":"28","author":"Twidwell J","year":"2016","unstructured":"Twidwell J, Levine L. Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016, 28:41-5. 10.1038\/ijir.2015.22","journal-title":"Int J Impot Res"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of Collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease","volume":"14","author":"Nguyen HM","year":"2017","unstructured":"Nguyen HM, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJ. Safety and efficacy of Collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease. J Sex Med. 2017, 14:1220-5. 10.1016\/j.jsxm.2017.08.008","journal-title":"J Sex Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.07.048","article-title":"Safety and efficacy of Collagenase Clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis","volume":"145","author":"Nguyen HM","year":"2020","unstructured":"Nguyen HM, Yousif A, Chung A, et al.. Safety and efficacy of Collagenase Clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis. Urology. 2020, 145:147-51. 10.1016\/j.urology.2020.07.048","journal-title":"Urology"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-188","article-title":"Intralesional collagenase Clostridium histolyticum for acute phase Peyronie's disease: a single-center, retrospective cohort study","volume":"11","author":"Hu MY","year":"2022","unstructured":"Hu MY, Sigalos JT, Walker DT, et al.. Intralesional collagenase Clostridium histolyticum for acute phase Peyronie's disease: a single-center, retrospective cohort study. Transl Androl Urol. 2022, 11:1074-82. 10.21037\/tau-22-188","journal-title":"Transl Androl Urol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.02.042","article-title":"Intralesional verapamil prevents the progression of Peyronie's disease","volume":"69","author":"Bennett NE","year":"2007","unstructured":"Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. Urology. 2007, 69:1181-4. 10.1016\/j.urology.2007.02.042","journal-title":"Urology"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.02159.x","article-title":"Analysis of intralesional verapamil (ILV) therapy for Peyronie's disease","volume":"8","author":"Cimmino C","year":"2011","unstructured":"Cimmino C, Bennett N. Analysis of intralesional verapamil (ILV) therapy for Peyronie's disease. Journal Sex Med. 2011, 8:17. 10.1111\/j.1743-6109.2010.02159.x","journal-title":"Journal Sex Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1159\/000138932","article-title":"Effects of calcium channel blockers on formalin-induced nociception and inflammation in rats","volume":"44","author":"G\u00fcrdal H","year":"1992","unstructured":"G\u00fcrdal H, Sara Y, Tulunay FC. Effects of calcium channel blockers on formalin-induced nociception and inflammation in rats. Pharmacology. 1992, 44:290-6. 10.1159\/000138932","journal-title":"Pharmacology"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla V","year":"2017","unstructured":"Favilla V, Russo GI, Zucchi A, et al.. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017, 5:771-5. 10.1111\/andr.12368","journal-title":"Andrology"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.190108","article-title":"Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie's disease: a prospective, open-label non-randomized clinical study","volume":"39","author":"Cocci A","year":"2021","unstructured":"Cocci A, Di Maida F, Cito G, et al.. Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie's disease: a prospective, open-label non-randomized clinical study. World J Mens Health. 2021, 39:352-7. 10.5534\/wjmh.190108","journal-title":"World J Mens Health"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.200048","article-title":"Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in Peyronie's disease: results from a phase III study","volume":"39","author":"Cai T","year":"2021","unstructured":"Cai T, Tiscione D, Favilla V, et al.. Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in Peyronie's disease: results from a phase III study. World J Mens Health. 2021, 39:526-32. 10.5534\/wjmh.200048","journal-title":"World J Mens Health"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2019.03.225","article-title":"Platelet-rich plasma therapy of Peyronie's disease","volume":"16","author":"Notsek M","year":"2019","unstructured":"Notsek M, Boiko M. Platelet-rich plasma therapy of Peyronie's disease. Journal Sex Med. 2019, 16:S70. 10.1016\/j.jsxm.2019.03.225","journal-title":"Journal Sex Med"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease","volume":"56","author":"Palmieri A","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, et al.. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol. 2009, 56:363-9. 10.1016\/j.eururo.2009.05.012","journal-title":"Eur Urol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-023-00673-w","article-title":"Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie's disease: a 10-year retrospective analysis","volume":"36","author":"Spirito L","year":"2024","unstructured":"Spirito L, Manfredi C, La Rocca R, et al.. Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie's disease: a 10-year retrospective analysis. Int J Impot Res. 2024, 36:135-9. 10.1038\/s41443-023-00673-w","journal-title":"Int J Impot Res"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2015.56.11.775","article-title":"Peyronie's disease and low intensity shock wave therapy: clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men","volume":"56","author":"Chung E","year":"2015","unstructured":"Chung E. Peyronie's disease and low intensity shock wave therapy: clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men. Korean J Urol. 2015, 56:775-80. 10.4111\/kju.2015.56.11.775","journal-title":"Korean J Urol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_40_21","article-title":"Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience","volume":"24","author":"Abdessater M","year":"2022","unstructured":"Abdessater M, Akakpo W, Kanbar A, et al.. Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience. Asian J Androl. 2022, 24:45-9. 10.4103\/aja.aja_40_21","journal-title":"Asian J Androl"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1111\/j.2047-2927.2012.00018.x","article-title":"Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease","volume":"1","author":"Mehrsai AR","year":"2013","unstructured":"Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease. Andrology. 2013, 1:129-32. 10.1111\/j.2047-2927.2012.00018.x","journal-title":"Andrology"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000116450.82816.2c","article-title":"A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease","volume":"171","author":"Di Stasi SM","year":"2004","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol. 2004, 171:1605-8. 10.1097\/01.ju.0000116450.82816.2c","journal-title":"J Urol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease","volume":"7","author":"Dell'Atti L","year":"2015","unstructured":"Dell'Atti L. Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease. Urol Ann. 2015, 7:345-9. 10.4103\/0974-7796.152048","journal-title":"Urol Ann"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial","volume":"35","author":"Palmieri A","year":"2012","unstructured":"Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012, 35:190-5. 10.1111\/j.1365-2605.2011.01226.x","journal-title":"Int J Androl"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2019.11.251","article-title":"Effect of low-dose PDE5i and low-energy shock wave on acute phase of Peyronie's disease","volume":"17","author":"Lu M","year":"2020","unstructured":"Lu M. Effect of low-dose PDE5i and low-energy shock wave on acute phase of Peyronie's disease. J Sex Med. 2020, 17:118-9. 10.1016\/j.jsxm.2019.11.251","journal-title":"J Sex Med"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2018.08.005","article-title":"Ten-year experience with multimodal treatment for acute phase Peyronie's disease: a real life clinical report","volume":"43","author":"Gallo L","year":"2019","unstructured":"Gallo L, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie's disease: a real life clinical report. Actas Urol Esp (Engl Ed). 2019, 43:182-9. 10.1016\/j.acuro.2018.08.005","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.07.1142","article-title":"Combination of Andropenis\u00ae penile extender and oral therapy (Peironimev \u00ae) versus intralesional verpamil for penile curvature due to Peyronie's disease: preliminary results of a randomized phase II trial","volume":"78","author":"Gontero P","year":"2011","unstructured":"Gontero P, Di Marco M, Giubilei G, et al.. Combination of Andropenis\u00ae penile extender and oral therapy (Peironimev \u00ae) versus intralesional verpamil for penile curvature due to Peyronie's disease: preliminary results of a randomized phase II trial. Urology. 2011, 78:S360. 10.1016\/j.urology.2011.07.1142","journal-title":"Urology"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2020.11.013","article-title":"Comparing and contrasting Peyronie's disease guidelines: points of consensus and deviation","volume":"18","author":"Manka MG","year":"2021","unstructured":"Manka MG, White LA, Yafi FA, Mulhall JP, Levine LA, Ziegelmann MJ. Comparing and contrasting Peyronie's disease guidelines: points of consensus and deviation. J Sex Med. 2021, 18:363-75. 10.1016\/j.jsxm.2020.11.013","journal-title":"J Sex Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2022.08.001","article-title":"A consistent lack of consistency in defining the acute and chronic phases of Peyronie's disease: a review of the contemporary literature","volume":"10","author":"Piraino J","year":"2022","unstructured":"Piraino J, Chaudhary H, Ames K, et al.. A consistent lack of consistency in defining the acute and chronic phases of Peyronie's disease: a review of the contemporary literature. Sex Med Rev. 2022, 10:698-713. 10.1016\/j.sxmr.2022.08.001","journal-title":"Sex Med Rev"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212454932","article-title":"Penile traction therapy and Peyronie's disease: a state of art review of the current literature","volume":"5","author":"Chung E","year":"2013","unstructured":"Chung E, Brock G. Penile traction therapy and Peyronie's disease: a state of art review of the current literature. Ther Adv Urol. 2013, 5:59-65. 10.1177\/1756287212454932","journal-title":"Ther Adv Urol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2020.10.003","article-title":"Outcomes of RestoreX penile traction therapy in men with Peyronie's disease: results from open label and follow-up phases","volume":"17","author":"Joseph J","year":"2020","unstructured":"Joseph J, Ziegelmann MJ, Alom M, Savage J, K\u00f6hler TS, Trost L. Outcomes of RestoreX penile traction therapy in men with Peyronie's disease: results from open label and follow-up phases. J Sex Med. 2020, 17:2462-71. 10.1016\/j.jsxm.2020.10.003","journal-title":"J Sex Med"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie's disease: AUA guideline","volume":"194","author":"Nehra A","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, et al.. Peyronie's disease: AUA guideline. J Urol. 2015, 194:745-53. 10.1016\/j.juro.2015.05.098","journal-title":"J Urol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.11.019","article-title":"The end of an era: withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European market","volume":"77","author":"Cocci A","year":"2020","unstructured":"Cocci A, Russo GI, Salamanca JI, Ralph D, Palmieri A, Mondaini N. The end of an era: withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European market. Eur Urol. 2020, 77:660-1. 10.1016\/j.eururo.2019.11.019","journal-title":"Eur Urol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01235.x","article-title":"RETRACTED: Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study","volume":"6","author":"Safarinejad MR","year":"2009","unstructured":"Safarinejad MR. RETRACTED: Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009, 6:1743-54. 10.1111\/j.1743-6109.2009.01235.x","journal-title":"J Sex Med"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease","volume":"106","author":"Safarinejad MR","year":"2010","unstructured":"Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int. 2010, 106:240-8. 10.1111\/j.1464-410X.2009.09041.x","journal-title":"BJU Int"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdtm.2020.06.001","article-title":"New insights into the pathogenesis of Peyronie's disease: a narrative review","volume":"6","author":"Krakhotkin DV","year":"2020","unstructured":"Krakhotkin DV, Chernylovskyi VA, Mottrie A, Greco F, Bugaev RA. New insights into the pathogenesis of Peyronie's disease: a narrative review. Chronic Dis Transl Med. 2020, 6:165-81. 10.1016\/j.cdtm.2020.06.001","journal-title":"Chronic Dis Transl Med"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.esxm.2018.08.002","article-title":"Verteporfin as a medical treatment in Peyronie's disease","volume":"6","author":"Mohede DC","year":"2018","unstructured":"Mohede DC, de Jong IJ, Bank RA, van Driel MF. Verteporfin as a medical treatment in Peyronie's disease. Sex Med. 2018, 6:302-8. 10.1016\/j.esxm.2018.08.002","journal-title":"Sex Med"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-2389","article-title":"Treatments of Peyronie's disease with Scutellaria baicalensis and surgery according to the disease course: a single-center retrospective study of 261 patients","volume":"10","author":"Li WJ","year":"2021","unstructured":"Li WJ, Bao J, Zheng DC, Guo J, Xie MK, Chen HY, Wang Z. Treatments of Peyronie's disease with Scutellaria baicalensis and surgery according to the disease course: a single-center retrospective study of 261 patients. Ann Palliat Med. 2021, 10:2979-89. 10.21037\/apm-20-2389","journal-title":"Ann Palliat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281585-acute-phase-peyronies-disease-where-do-we-stand","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T09:24:23Z","timestamp":1723886663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281585-acute-phase-peyronies-disease-where-do-we-stand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":112,"URL":"https:\/\/doi.org\/10.7759\/cureus.67054","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}